Acquisition by Blake Borgeson of 1734 shares of Recursion Pharmaceuticals subject to Rule 16b-3
| RXRX Stock | USD 7.49 0.46 5.79% |
Slightly above 62% of Recursion Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Recursion Pharmaceuticals suggests that many traders are alarmed. Recursion Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Recursion Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Recursion |
Filed transaction by Recursion Pharmaceuticals Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Recursion Pharmaceuticals Fundamental Analysis
We analyze Recursion Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Recursion Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Recursion Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Recursion Pharmaceuticals is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Recursion Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Recursion Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Recursion Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Recursion Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Recursion Pharmaceuticals Related Equities
| ENVB | Enveric Biosciences | 19.05 | ||||
| OCEA | Ocean Biomedical | 7.25 | ||||
| DAWN | Day One | 1.64 | ||||
| RLAY | Relay Therapeutics | 1.09 | ||||
| IMMX | Immix Biopharma | 0.87 | ||||
| ABOS | Acumen Pharmaceuticals | 1.08 | ||||
| INZY | Inozyme Pharma | 2.42 | ||||
| AFMD | Affimed NV | 2.94 | ||||
| XFOR | X4 Pharmaceuticals | 5.41 | ||||
| SANA | Sana Biotechnology | 5.71 | ||||
| HEPA | Hepion Pharmaceuticals | 6.15 | ||||
| CNSP | Cns Pharmaceuticals | 8.33 | ||||
| ABSI | Absci Corp | 8.90 |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.